Wellington Management Group
VRDN icon

Wellington Management Group’s Viridian Therapeutics VRDN Stock Holding History

Wellington Management Group’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57.5M Buy
3,128,362
+49,808
+2% +$802K 0.01% 716
2026
Q1 		$60.2M Buy
3,078,554
+1,107,143
+56% +$32.9M 0.01% 681
2025
Q4 		$61.4M Buy
1,971,411
+848,879
+76% +$23.3M 0.01% 677
2025
Q3 		$24.2M Buy
1,122,532
+851,989
+315% +$15.4M ﹤0.01% 952
2025
Q2 		$3.78M Buy
270,543
+21,373
+9% +$290K ﹤0.01% 1442
2025
Q1 		$3.36M Buy
249,170
+24,686
+11% +$420K ﹤0.01% 1454
2024
Q4 		$4.3M Sell
224,484
-11,503
-5% -$250K ﹤0.01% 1381
2024
Q3 		$5.37M Sell
235,987
-48,057
-17% -$786K ﹤0.01% 1315
2024
Q2 		$3.7M Buy
284,044
+43,215
+18% +$598K ﹤0.01% 1385
2024
Q1 		$4.22M Buy
240,829
+48,732
+25% +$945K ﹤0.01% 1365
2023
Q4 		$4.18M Sell
192,097
-23,551
-11% -$372K ﹤0.01% 1350
2023
Q3 		$3.31M Buy
215,648
+43,349
+25% +$827K ﹤0.01% 1380
2023
Q2 		$4.1M Buy
172,299
+47,903
+39% +$1.23M ﹤0.01% 1325
2023
Q1 		$3.16M Buy
124,396
+3,893
+3% +$125K ﹤0.01% 1394
2022
Q4 		$3.52M Buy
+120,503
New +$2.78M ﹤0.01% 1366
2021
Q3 		– Sell
-578,560
Closed -$10.6M – 2270
2021
Q2 		$10.6M Hold
578,560
– – ﹤0.01% 1253
2021
Q1 		$9.67M Buy
+578,560
New +$10.8M ﹤0.01% 1250

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Wellington Management Group's VRDN Position: Q2 2026 in Review

Wellington Management Group increased its Viridian Therapeutics (VRDN) stake by 1.6% in Q2 2026, buying an estimated $802K and bringing the position to 3,128,362 shares worth $57.5M. The position accounts for 0.01% of the portfolio, ranked #716.

Wellington Management Group first reported a position in VRDN in Q1 2021 and has held it in 17 quarters since. The position peaked at $61.4M in Q4 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Wellington Management Group held 3,128,362 shares of Viridian Therapeutics worth $57.5M as of Q2 2026.
  • Wellington Management Group bought 49,808 Viridian Therapeutics shares in Q2 2026, an estimated $802K.
  • Viridian Therapeutics made up 0.01% of Wellington Management Group's portfolio in Q2 2026, its #716 holding.
  • Wellington Management Group first reported a position in Viridian Therapeutics in Q1 2021 and has held it in 17 quarters since.
  • Wellington Management Group's Viridian Therapeutics position peaked at $61.4M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.